Erratum

Erratum to Issaenko OA, et al. Cell Cycle Volume 11, Issue 9; pp. 1804-17

Volume 11, Issue 18   September 15, 2012
Page 3518
http://dx.doi.org/10.4161/cc.22096
Authors: Olga A. Issaenko and Alexander Yu Amerik

View affiliations

Erratum to:
OA Issaenko, AY Amerik. Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell Cycle 2012; 11: 1804-17
PMID: 22510564 DOI: 10.4161/cc.20174

Received: September 5, 2012; Accepted: September 5, 2012; Published Online: September 15, 2012

Preview:



Full Text

Olga A. Issaenko and Alexander Yu Amerik, authors of the recently published paper, "Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes" wish to make the following clarifications regarding compound names referenced therein.

1. The authors note that on pages 1809 and 1810, the label and the legend for Figure 4B appeared incorrectly in part. Compound name “KVI-14” should instead read “RA-14.”

2. The authors note that small molecule inhibitor RA-9 used in this study is structurally different from another chalcone-derivative “compound 10 RA-9” referenced in 1. To avoid further confusion, in Table 1 below, authors provide chemical formulas, other known names and known references for chalcone-derivatives used in this study.

Table 1. Chemical formulas, other known names and known references for chalcone-derivatives.

Compound R1 R2 P Reported IC50 (µM)
HeLa cells		 Alternative nomenclature Reference
RA-1 Cl Cl -CO-Phenylalanine 0.32 1
AM146 H Cl CH3 1.5–1.83 RAMB1 2, 3
RA-9 H NO2 H 2.37 RAMB9 2
RA-14 H NO2 CH3 2.03 KVI-14, RAMB14 2

Acknowledgment



Proprietary rights and synthesis of compounds: inquiries to Saeed R. Khan, The John Hopkins University, Baltimore, Maryland 21231; E-mail: saeed.khan2@fda.hhs.gov.

References



1. Bazzaro M, Anchoori RK, Mudiam MK, Issaenko O, Kumar S, Karanam B, et al. α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J Med Chem 2011; 54:449-56; PMID: 21186794; DOI: 10.1021/jm100589p.

2. Issaenko OA, Amerik AY. Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell Cycle 2012; 11:1804-17; PMID: 22510564; DOI: 10.4161/cc.20174.

3. Anchoori RK, Khan SR, Sueblinvong T, Felthauser A, Iizuka Y, Gavioli R, et al. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. PLoS One 2011; 6:e23888; PMID: 21909374; DOI: 10.1371/journal.pone.0023888.

License



Creative Commons License
This is an Open Access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced and reused for non-commercial purposes, provided the original source is properly cited.
Top
Back
  • Acknowledgment
  • References
  • License
Jump to Section
Advertisements